Omnicell, Inc.
OMCLHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Omnicell, Inc. focuses on Health Information Services services and products. Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. Valued at $1.96B, OMCL is a small-cap name in its sector. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process.
Market Cap
$1.96B
Beta
0.96
P/E (TTM)
98.09
P/E (Fwd)
19.66
EPS (TTM)
$0.44
EPS (Fwd)
$2.19
ROE
1.6%
ROA
1.2%
Cash
$239.2M
Total Debt
$202.2M
Free CF
$112.6M
52W Change
39.1%
Annual Financials
Cash vs Debt
Omnicell, Inc. holds $239.2M in cash against $202.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $112.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 1.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.2% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $1.13B (2021) to $1.18B (2025).
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing OMCL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.